Sanah Rana, MD
Endocrinology, Diabetes & Metabolism · Alexander City, ALNPI 1013303171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,524 and has fallen 61.2% since, to $591 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 136 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$407
- Xeris Pharmaceuticals, Inc.$266
- Boehringer Ingelheim$225
- Bayer$172
- IBSA Pharma Inc.$162
- Radius Health, Inc.$162
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,64999%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $407 |
| Xeris Pharmaceuticals, Inc. | 17 | $266 |
| Boehringer Ingelheim | 13 | $225 |
| Bayer | 7 | $172 |
| IBSA Pharma Inc. | 7 | $162 |
| Radius Health, Inc. | 6 | $162 |
| Tandem Diabetes Care, Inc. | 3 | $114 |
| Corcept Therapeutics | 5 | $111 |
| Lilly USA, LLC | 6 | $108 |
| Acadia Pharmaceuticals Inc | 5 | $108 |
| Amgen(2 entities) | 4 | $89 |
| AstraZeneca | 4 | $86 |
| Medtronic | 4 | $83 |
| Amarin Pharma, Inc. | 4 | $73 |
| Zealand Pharma US, Inc. | 3 | $61 |
| Pfizer | 4 | $59 |
| GRT US Holding, Inc. | 3 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Insulet Corporation | 2 | $44 |
| Lifescan, Inc. | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Nevro Corp. | 1 | $24 |
| Dexcom, Inc. | 2 | $24 |
| Mylan Specialty L.p. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Cequr Corporation | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$2,673 in reported general payments places this provider in the 30th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $122,308 |
| MounjaroTirzepatide | 34 | $38,878 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $38,108 |
| Repatha SureclickEvolocumab | 22 | $34,197 |
| SynthroidLevothyroxine Sodium | 248 | $24,948 |
| TrulicityDulaglutide | 14 | $19,206 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $8,744 |
| TirosintLevothyroxine Sodium | 19 | $5,817 |
| HumalogInsulin Lispro | 14 | $3,571 |
| Alendronate Sodium | 119 | $3,209 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 26 | $2,402 |
| Cinacalcet Hcl | 14 | $2,197 |
| Levothyroxine Sodium | 264 | $1,910 |
| Calcitriol | 37 | $1,693 |
| Ezetimibe | 50 | $1,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $407 | $122,30895 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $108 | $61,65562 claims |
| IBSA Pharma Inc.Tirosint | $162 | $5,81719 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $1,910264 claims |
| PfizerLevoxyl | $59 | $43318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Alexander City
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.